reports
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery Syst...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs,” please visi...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: It shouldn’t be surprising that analysts at Markets and Research estimate the global diabetes drug market at $63.1 billion in 2021 on its way to $82.93 billion in 2027, while th...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-De...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Can Diabetes, Weight-Loss Drugs Get Even Better?”,please visit: The prest...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hy...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: In its 2021 industry report, estimated the global anti-hypertensive drugs market at $24.17 billion in 2020 on its way to reach $27.81 billion in 2025. All told, hypertension costs the country on average ann...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Tr...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “The Power of Science to Stop a Killer,” please visit: Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Del...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: The fact remains that an estimated 1.1 billion people smoked cigarettes in 2019. According to stats from the World Health Organization, a stunning 780 million people said they want to quit. As a result, people look to a multitud...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery T...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Nicotine Surges as Smoking Sags,” please visit: Seems like yesterday people were smoking cigarettes everywhere; many people still have memories of Grandpa puffing on his Ca...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: The market is certainly worth entering. Consider that Reportlinker.com estimates the global anti-hypertensive drugs market to be $24.37 billion in 2021 and growing 3.4% an...
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension ...
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Hypertension: The Silent Killer Making Loud Noise for Investors,” please visit: Hypertension, or high blood pressure, is rampant in America. An estimat...
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hyper...
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: Controlling blood pressure is essential to health. High blood pressure is a primary or contributing cause of death in almost 500,000 deaths a year, and...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hy...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space,” please visit: One of the most pervasive diseases in first-world count...
Nexus Gold Announces Warrant Extension and Repricing
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2021) - Nexus Gold Corp. (TSXV: NXS) (OTCQB: NXXGF) (FSE: N6E) ("Nexus" or the "Company") is pleased to announce that it has extended the expiry and reduced the exercise price (the "Amendment") to the terms of an aggregate of 12,532,477 warrants (each, a "Warrant") issued by the Company. More particularly, the Company has amended the terms of 8,649,913 warrants set to expire on February 26, 2021. Of this series, all are held by non-insiders and exercisable at $0.18 (the "February Warrants"). The date of expiration of the February War...
- Alison Turner
Monarch Gold - Wasamac sale and spin out
Monarch Gold has entered a definitive agreement with Yamana Gold to sell its flagship Wasamac property and its Camflo mill and tailings facilities to Yamana for C$152m, or C$0.48 per share on a fully diluted basis. Monarch’s remaining assets Croinor, McKenzie Break, Swanson and Beaufor (plus its Beacon Mill, related liabilities and C$14m in cash) will be spun out as a separate company (SpinCo). Management estimates of the SpinCo valuation of C$47.5m, of C$0.15 per share, would imply an overall d...
- Sid Rajeev
Monarch Gold (MQR): Wasamac a winner
Edison Investment Research Limited Monarch Gold (MQR): Wasamac a winner 23-Oct-2020 / 08:00 GMT/BST London, UK, 23 October 2020 Monarch Gold (MQR): Wasamac a winner Monarch Gold (MQR) has a diverse portfolio of assets across (former) producers, development and exploration in the established and highly prospective Abitibi gold belt, with its 2.6Moz Wasamac project the main focus at present. The 2018 feasibility study (FS) pointed to average annual production of 142koz over the 10-year life of the mine. A favourable operating cost base and optimal logistics and infrastructure gen...
EML Payments (EML): Storing up value
Edison Investment Research Limited EML Payments (EML): Storing up value 22-Oct-2020 / 21:00 GMT/BST London, UK, 22 October 2020 EML Payments (EML): Storing up value EML Payments is a specialist payment solutions provider with a focus on the prepaid market. The group's strategy is to use acquisitions supported by organic development to establish strong positions across a diverse range of use cases and markets. EML now operates in 28 countries and has grown revenues at a five-year CAGR of 53%. While COVID-19 has slowed the pace of growth in the short term, the business is well-f...
- Sid Rajeev
Monarch Gold Corporation (TSX: MQR /OTCQX: MRQRF) Strengthens Balance ...
Fundamental Research Corp has issued a report entitled “Monarch Gold Corporation (TSX: MQR /OTCQX: MRQRF) Strengthens Balance Sheet / Advancing Wasamac†and dated September 4, 2020. The full report is now at MQR is an FRC Top Pick
DGAP-News: Lexaria Bioscience Corp.: Lexaria Bioscience announces R&D ...
DGAP-News: Lexaria Bioscience Corp. / Key word(s): Agreement Lexaria Bioscience Corp.: Lexaria Bioscience announces R&D agreement with British American Tobacco 01.09.2020 / 07:47 The issuer is solely responsible for the content of this announcement. Lexaria Bioscience announces R&D agreement with British American Tobacco Kelowna, British Columbia- August 31, 2020 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered a research and development ("R&D") framework agree...
- Sid Rajeev
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.